CEUS Evaluation of Bowel Perfusion in Necrotizing Enterocolitis

PHASE3TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

May 7, 2024

Study Completion Date

May 7, 2024

Conditions
Necrotizing Enterocolitis of NewbornBowel Ischemic
Interventions
DRUG

Sulfur hexafluoride lipid-type A microspheres

Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.

Trial Locations (1)

19104

The Children's Hospital of Philadelphia, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bracco Diagnostics, Inc

INDUSTRY

lead

Children's Hospital of Philadelphia

OTHER